Cargando…

Selection of breast cancer subtypes to improve benefits of intensive dose‑dense chemotherapy: A systematic meta‑analysis

Breast cancer (BC) is the most commonly diagnosed cancer and the second leading cause of cancer mortality among women worldwide. A large number of patients experience recurrence and BC-associated mortality following adjuvant chemotherapy. The present study aimed to determine the most suitable pathol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Su, Dan, Zhang, Tianqi, Huang, Huimin, Su, Xiaoyu, Li, Ying, Wei, Xiuyan, Zhang, Yingshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665989/ https://www.ncbi.nlm.nih.gov/pubmed/38028182 http://dx.doi.org/10.3892/ol.2023.14136

Ejemplares similares

Survival benefit of pure dose-dense chemotherapy in breast cancer: a meta-analysis of randomized controlled trials
por: Zhou, Wenqi, et al.
Publicado: (2018)

Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer
por: Kümmel, S, et al.
Publicado: (2006)

Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer
por: Puglisi, Fabio, et al.
Publicado: (2021)

Dose-dense adjuvant chemotherapy for primary breast cancer
por: Fornier, Monica, et al.
Publicado: (2005)

Efficacy and safety of dose-dense chemotherapy in urothelial carcinoma
por: Zhu, Chenjing, et al.
Publicado: (2017)

Adding Epoetin Alfa to Intense Dose-Dense Adjuvant Chemotherapy for Breast Cancer: Randomized Clinical Trial
por: Moebus, Volker, et al.
Publicado: (2013)

Dose-dense chemotherapy for breast cancer: the story so far
por: Hudis, C
Publicado: (2000)

Dose-Dense Chemotherapy in Nonmetastatic Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials
por: Bonilla, Luisa, et al.
Publicado: (2010)

Pneumocystis jirovecii in a patient on dose‐dense chemotherapy for early breast cancer
por: Khoo, Chloe, et al.
Publicado: (2019)

An observational study of dose dense chemotherapy with lipegfilgrastim support in early breast cancer
por: Rashed, Ahmed, et al.
Publicado: (2023)

Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study
por: Shi, Tingyan, et al.
Publicado: (2019)

Phase II trial of dose-dense chemotherapy followed by dose-intense erlotinib for patients with newly diagnosed metastatic non-small cell lung cancer
por: PETTY, W. JEFFREY, et al.
Publicado: (2013)

Molecular subtypes of breast cancer and amplification of topoisomerase IIα: predictive role in dose intensive adjuvant chemotherapy
por: Hannemann, J, et al.
Publicado: (2006)

Impressive Response to Dose-Dense Chemotherapy in a Patient with NUT Midline Carcinoma
por: Maur, Michela, et al.
Publicado: (2015)

Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer
por: Mirzaei, Hamid Reza, et al.
Publicado: (2013)

Pneumocystis jirovecii Pneumonia in a Patient with Breast Cancer Receiving Neoadjuvant Dose-dense Chemotherapy
por: Watanabe, Hirofumi, et al.
Publicado: (2019)

Pneumocystis jirovecii Pneumonia in Three Patients With Breast Cancer Receiving Neoadjuvant Dose-Dense Chemotherapy
por: Shiiba, Ritsuya, et al.
Publicado: (2022)

Dose-Dense Docetaxel versus Weekly Paclitaxel following Dose-Dense Epirubicin and Cyclophosphamide as Adjuvant Chemotherapy in Node-Positive Breast Cancer Patients: A Retrospective Cohort Analysis
por: Khoshroo, Sara, et al.
Publicado: (2021)

Prognostic Impact of Stromal Immune Infiltration before and after Neoadjuvant Chemotherapy (NAC) in Triple Negative Inflammatory Breast Cancers (TNIBC) Treated with Dose-Dense Dose-Intense NAC
por: Campedel, Luca, et al.
Publicado: (2020)

Dose intensity in cancer chemotherapy.
por: Dodwell, D. J., et al.
Publicado: (1990)

HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients
por: Del Mastro, L, et al.
Publicado: (2005)

High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancer
por: Brain, E, et al.
Publicado: (2011)

Does dose-dense neoadjuvant chemotherapy have clinically significant prognostic value in breast cancer?: A meta-analysis of 3,724 patients
por: Ding, Yuqin, et al.
Publicado: (2020)

Potential Benefits of Neoadjuvant Chemotherapy in Clinically Node-Positive Luminal Subtype(−) Breast Cancer
por: Kim, Hyung Suk, et al.
Publicado: (2019)

Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy
por: Giacchetti, Sylvie, et al.
Publicado: (2022)

Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer
por: Li, Qing, et al.
Publicado: (2020)

Comparison of Oncologic Outcomes of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (ddMVAC) with Gemcitabine and Cisplatin (GC) as Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Systematic Review and Meta-Analysis
por: Chung, Doo Yong, et al.
Publicado: (2021)

Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab
por: Wang, Lize, et al.
Publicado: (2021)

Dose-dense Temozolomide: Is It Still Promising?
por: NAGANE, Motoo
Publicado: (2015)

Therapeutic responses to chemotherapy or immunotherapy by molecular subtype in bladder cancer patients: A meta-analysis and systematic review
por: Wang, Shunde, et al.
Publicado: (2023)

Comparative hematological profiles for dose-dense vs. regular anthracycline-based neoadjuvant chemotherapy in non-metastatic breast cancer
por: Popovici, Dorel, et al.
Publicado: (2021)

Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours
por: Fizazi, K, et al.
Publicado: (2002)

Efficacy, safety and proper dose analysis of PEGylated granulocyte colony-stimulating factor as support for dose-dense adjuvant chemotherapy in node positive Chinese breast cancer patients
por: Zhang, Fan, et al.
Publicado: (2017)

The Benefit of Post-Mastectomy Radiotherapy in ypN0 Patients after Neoadjuvant Chemotherapy According to Molecular Subtypes
por: Cho, Won Kyung, et al.
Publicado: (2019)

Measurement of molecular biomarkers that predict the tumor response in estrogen receptor-positive breast cancers after dose-dense (biweekly) paclitaxel/carboplatin neoadjuvant chemotherapy
por: Zhu, Teng, et al.
Publicado: (2017)

Prognostic and predictive impact of gene expression in node‐positive early breast cancer patients receiving dose‐dense versus standard‐dose adjuvant chemotherapy
por: Reinisch, Mattea, et al.
Publicado: (2023)

Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma
por: Jethava, Y, et al.
Publicado: (2016)

Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma
por: Jethava, Y, et al.
Publicado: (2016)

A case of squamous cell carcinoma of the breast achieved a pathological complete response after dose-dense AC + dose-dense PTX
por: Araki, Misato, et al.
Publicado: (2023)

Retrospective Study of the Safety and Efficacy of Anlotinib Combined With Dose-Dense Temozolomide in Patients With Recurrent Glioblastoma
por: She, Lei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_51al302ck9p223r5ndo7ko7tf5